Document is current

Article History

Received: 16 June 2023

Accepted: 12 July 2024

First Online: 31 July 2024

Declarations

:

: Not applicable.

: Not applicable.

: YZ holds shares at General Biomics Inc. HT has, in the last 5 years, received research support from the Canada Research Chair Program, the National Multiple Sclerosis Society, the Canadian Institutes of Health Research, the Multiple Sclerosis Society of Canada, the Multiple Sclerosis Scientific Research Foundation, and the EDMUS Foundation (“Fondation EDMUS contre la sclérose en plaques”) and, in addition, in the last 5 years, has had travel expenses or registration fees prepaid or reimbursed to present at CME conferences from the Consortium of MS Centres (2018), National MS Society (2018), ECTRIMS/ACTRIMS (2017–2022), and American Academy of Neurology (2019). Speaker honoraria are either declined or donated to an MS charity or to an unrestricted grant for use by HT’s research group. EEL has received honoraria over the last 5 years for consulting for Bristol Myers Squibb, Genentech, TG Therapeutics, NGM Bio, Janssen, Biogen, Genzyme, Alexion, EMD Serono, Celgene, and Teva. She has received research support from Genentech, the National Institutes of Health (NIH K23 NS107624 and KL2 TR001862), the Race to Erase MS, and the Robert E Leet and Clara Guthrie Patterson Trust. She is an assistant editor for <i>Annals of Neurology</i>. The remaining authors declare that they have no competing interests.